CROSSING - A new treatment for Eosinophilic Esophagitis

Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE) is caused by elevated levels of a type of white blood cell called eosinophils in the oesophagus (the tube from the throat to the stomach). Elevated levels of eosinophils and a protein made by the body called Thymic Stromal Lymphopoietin (TSLP)  cause inflammation of the oesophagus.

Tezepelumab is a man-made antibody that works by blocking the effects of TSLP. Antibodies are proteins naturally produced by the body to neutralize foreign substances that enter the body. By blocking the effects of TSLP, tezepelumab may help decrease inflammation in the oesophagus and improve difficulties in swallowing.

We are doing this study to learn more about tezepelumab. We would like to know if it could be an effective and safe treatment for EoE. We also aim to better understand the condition and associated health problems.

Trial Status
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
IBD Clinical Trials Unit
What you need to know

Who can take part?

  • Participants aged 12 -80
  • Body weight ≥ 40 kg
  • Confirmed diagnosis of Eosinophilic Eosophagitis
  • Difficultly swallowing
  • Prior treatment with standard medications
  • Stable diet for at least 8 weeks


  • Certain other diseases may exclude you from participating
  • Strictures
  • People requiring a feeding tube may not participate
  • Current or recent infection
  • Immunosuppression
  • Previous cancer diagnosis
  • Certain medications may make you ineligible to participate

What is involved for you?

  • Medical history and collection of demographic information
  • Vital signs
  • Electrocardiogram
  • Physical exam
  • Blood and urine tests
  • Pregnancy tests for women with childbearing potential
  • Endoscopy with oesophagus tissue biopsy
  • Daily diary completion
  • Questionnaires
  • Two injections every 4 weeks of treatment/placebo

Trial dates

April 2022 to December 2023

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|